Literature DB >> 33773904

Liver Disease is Associated with Increased Mortality and Major Morbidity After Infra-Inguinal Bypass but not After Endovascular Intervention.

Sara L Zettervall1, Kirsten Dansey2, Amy Evenson3, Marc L Schermerhorn2.   

Abstract

OBJECTIVE: Liver disease increases mortality after abdominal surgery, including endovascular aortic aneurysm repair. However, its effect on mortality and morbidity after endovascular and open management of peripheral vascular disease has not been widely evaluated.
METHODS: The National Surgical Quality Improvement Program was used to evaluate patients undergoing infra-inguinal bypass and endovascular intervention (2005 - 2016). Aspartate aminotransferase to platelet ratio (APRI score) is a non-invasive tool recommended by the World Health Organisation to identify liver disease and was calculated for all patients. A ratio of > 0.5 was used to identify patients with liver fibrosis. Demographics, comorbidities, and 30 day outcomes were evaluated for patients with and without liver fibrosis. A subgroup analysis was completed in patients with APRI scores > 0.5, to evaluate the effect of increasing Model for End-Stage Liver Disease (MELD) scores on outcomes. Multivariable regression was used to account for differences in baseline factors.
RESULTS: In total, 17 603 patients underwent infra-inguinal bypasses. Fibrosis was associated with higher mortality (3.8% vs. 2.4%; p < .001), major complications (23% vs. 20%; p = .020), pulmonary (5.1% vs. 2.9%; p < .001), and renal complications (1.9% vs. 1.1%; p = .007) after bypass. These differences persisted following multivariable adjustment. Altogether, 7 830 patients underwent endovascular intervention. Fibrosis was also associated with higher mortality (4.7% vs. 2.2%; p < .001), pulmonary (3.9% vs. 2.5%; p = .022), and renal complications (1.9% vs. 0.8%; p = .003) after endovascular intervention. After adjustment, only renal complications persisted. In a subgroup analysis of patients with liver fibrosis, morbidity (31% vs. 17%; p < .001) and mortality (7.2% vs. 1.8%; p < .001) increased after bypass among those with MELD scores > 15 but not after endovascular intervention.
CONCLUSION: Liver fibrosis was associated with higher 30 day mortality and major complications after infra-inguinal bypass, with outcomes worsening as MELD scores increased. Surgeons may consider an endovascular first approach in managing peripheral arterial disease among those with liver fibrosis.
Copyright © 2021 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bypass; Cirrhosis; Liver fibrosis; Peripheral arterial disease

Mesh:

Year:  2021        PMID: 33773904      PMCID: PMC8217150          DOI: 10.1016/j.ejvs.2021.02.015

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   6.427


  16 in total

1.  Toward robust information: data quality and inter-rater reliability in the American College of Surgeons National Surgical Quality Improvement Program.

Authors:  Mira Shiloach; Stanley K Frencher; Janet E Steeger; Katherine S Rowell; Kristine Bartzokis; Majed G Tomeh; Karen E Richards; Clifford Y Ko; Bruce L Hall
Journal:  J Am Coll Surg       Date:  2009-11-22       Impact factor: 6.113

Review 2.  Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis.

Authors:  Zhong-Hua Lin; Yong-Ning Xin; Quan-Jiang Dong; Qing Wang; Xiang-Jun Jiang; Shu-Hui Zhan; Ying Sun; Shi-Ying Xuan
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

Review 3.  Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis.

Authors:  Guangqin Xiao; Jiayin Yang; Lunan Yan
Journal:  Hepatology       Date:  2014-11-24       Impact factor: 17.425

4.  A population-based analysis of endovascular aortic stent graft therapy in patients with liver cirrhosis.

Authors:  An-Hsun Chou; Ching-Chang Chen; Yu-Sheng Lin; Ming-Shyan Lin; Victor Chien-Chia Wu; Pei-Chi Ting; Shao-Wei Chen
Journal:  J Vasc Surg       Date:  2018-10-24       Impact factor: 4.268

5.  Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis.

Authors:  Puneeta Tandon; Guadalupe Garcia-Tsao
Journal:  Clin Gastroenterol Hepatol       Date:  2010-12-08       Impact factor: 11.382

6.  Association of Model for End-Stage Liver Disease Score With Mortality in Emergency General Surgery Patients.

Authors:  Joaquim M Havens; Alexandra B Columbus; Olubode A Olufajo; Reza Askari; Ali Salim; Kenneth B Christopher
Journal:  JAMA Surg       Date:  2016-07-20       Impact factor: 14.766

7.  The role of Model for End-Stage Liver Disease (MELD) score in predicting outcomes for lower extremity bypass.

Authors:  Brianna M Krafcik; Alik Farber; Mohammad H Eslami; Jeffrey A Kalish; Denis Rybin; Gheorghe Doros; Nishant K Shah; Jeffrey J Siracuse
Journal:  J Vasc Surg       Date:  2016-03-16       Impact factor: 4.268

Review 8.  Outcomes of patients with cirrhosis undergoing non-hepatic surgery: risk assessment and management.

Authors:  Farida Millwala; Geoffrey C Nguyen; Paul J Thuluvath
Journal:  World J Gastroenterol       Date:  2007-08-14       Impact factor: 5.742

9.  A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis.

Authors:  Claudia Fagundes; Rogelio Barreto; Mónica Guevara; Elisabet Garcia; Elsa Solà; Ezequiel Rodríguez; Isabel Graupera; Xavier Ariza; Gustavo Pereira; Ignacio Alfaro; Andrés Cárdenas; Javier Fernández; Esteban Poch; Pere Ginès
Journal:  J Hepatol       Date:  2013-05-10       Impact factor: 25.083

10.  MELD score as a predictor of mortality, length of hospital stay, and disease burden: A single-center retrospective study in 39,323 inpatients.

Authors:  Jan A Roth; Carl Chrobak; Sabine Schädelin; Balthasar L Hug
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.